Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Greisner

Allergy & Immunology Lexington, KY Medical Doctor

NPI 1720095334 CMS profile 259552

171 North Eagle Creek Drive, Suite 106, Lexington, KY 40509

Open in the dashboard

General payments

$39,339

701 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,761,483 paid to institutions, not to them · program years 2019–2025

Through program year 2025, William Greisner of Lexington, KY is reported in the CMS Open Payments database as having received $39,339 across 701 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,761,483 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,404 134
2024 General $8,001 93
2023 General $5,531 118
2022 General $2,755 121
2021 General $2,403 103
2020 General $1,860 65
2019 General $4,384 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Greisner
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to William Greisner were reported at $14,404. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year William Greisner Allergy & Immunology median Middle half National median
2019 $4,384 $594 $163–$1,512 $163
2020 $1,860 $426 $106–$1,233 $114
2021 $2,403 $638 $157–$1,708 $132
2022 $2,755 $790 $205–$1,961 $149
2023 $5,531 $852 $220–$2,147 $160
2024 $8,001 $865 $203–$2,267 $164
2025 $14,404 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech USA, Inc. $8,511 41 payments
  2. Lilly USA, LLC $5,383 9 payments
  3. kaleo, Inc. $3,722 35 payments
  4. OptiNose US, Inc. $3,056 14 payments
  5. Genzyme Corporation $3,030 93 payments
  6. AstraZeneca Pharmaceuticals LP $2,283 82 payments
  7. Novartis Pharmaceuticals Corporation $2,085 15 payments
  8. GlaxoSmithKline, LLC. $1,669 89 payments
  9. Regeneron Healthcare Solutions, Inc. $1,464 44 payments
  10. CSL Behring $1,183 55 payments
  11. Other $6,954 224 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $18,237 12 payments
  2. Food and Beverage $18,205 674 payments
  3. Travel and Lodging $1,348 9 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,300 2 payments
  5. Education $224 3 payments
  6. Honoraria $25 1 payment
Products named General payments · program years 2019–2025
  1. Xolair $8,651 44 payments
  2. EBGLYSS $5,383 9 payments
  3. DUPIXENT Immunology $3,771 114 payments
  4. AUVI-Q $3,190 7 payments
  5. Xhance $3,056 14 payments
  6. FASENRA $1,114 27 payments
  7. NUCALA $1,078 54 payments
  8. DUPIXENT Inflammation And Immunology $999 35 payments
  9. TEZSPIRE $709 6 payments
  10. Orladeyo $673 11 payments
  11. Other $11,015 452 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,202

Median for Allergy/ Immunology: 449

Drug cost

$287,881

Median for Allergy/ Immunology: $169,700

Branded share of claims

47.5%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xolair Omalizumab Brand 23 $62,685
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 62 $48,377
Cuvitru Immun Glob G(Igg)/Gly/Iga Ov50 Brand 23 $40,284
Symbicort Budesonide/Formoterol Fumarate Brand 80 $25,985
Breo Ellipta Fluticasone/Vilanterol Brand 53 $25,401
Spiriva Respimat Tiotropium Bromide Brand 32 $20,873
Advair Hfa Fluticasone Propion/Salmeterol Brand 21 $11,790
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 59 $10,335
Epinephrine Generic 34 $8,851
Qvar Redihaler Beclomethasone Dipropionate Brand 16 $6,769

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$52,676

Medicare's payments for the services billed

Medicare patients

183

Average age 71

Services billed

5,357

113 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 54%
Depression 27%
Diabetes 23%
Ischemic heart disease 18%
COPD 16%
Osteoporosis 16%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xolair
  • Genentech USA, Inc. $5,771
  • Genentech, Inc. $19
$5,790 23 —
DUPIXENT
  • GENZYME CORPORATION $571
  • Regeneron Healthcare Solutions, Inc. $155
  • SANOFI-AVENTIS U.S. LLC $99
$825 — —
NUCALA
  • GlaxoSmithKline, LLC. $218
$218 — —
TEZSPIRE
  • Amgen Inc. $128
  • AstraZeneca Pharmaceuticals LP $61
$188 — —
AYVAKIT
  • Blueprint Medicines Corporation $169
$169 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

701 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record